SRR934940
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | B4E10042-052D-4DC4-BC94-FF1D5D4632C0 | — | — | 0.947 |
| 2 | SRR934942 | — | — | 0.927 |
| 3 | AD62B8A4-6AB8-4C99-80F5-98A1C085027D | — | — | 0.925 |
| 4 | SRR934871 | — | — | 0.913 |
| 5 | 4880B586-BA92-48B2-A233-5C245D2E31C0 | — | — | 0.913 |
| 6 | BF513557-1518-4843-9F62-837B557D4CAB | — | — | 0.912 |
| 7 | 4942E435-61E6-4A43-B031-4E08F0B41186 | — | — | 0.908 |
| 8 | 165395C6-1028-49DF-B15D-4D8064D00995 | — | — | 0.901 |
| 9 | SRR934946 | — | — | 0.901 |
| 10 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.697 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.628 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.548 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.516 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.505 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.463 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.440 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.422 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.396 | Inavolisib | — uncovered |
| APOPTOSIS | 0.392 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.381 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.348 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.321 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.301 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.292 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.280 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.264 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.259 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.254 | Inavolisib | — uncovered |